Siemens Healthineers held a ribbon-cutting ceremony for its $300 million expansion of its in vitro diagnostic test manufacturing and R&D facility in Walpole, Massachusetts.
Currently, the flagship Walpole facility employs more than 900 employees and is Healthineers’ main manufacturing plant for tests running on its Advia Centaur family of immunoassay instruments, as well as consumables for the company’s molecular and blood gas testing hardware.
The 500,000-square-foot facility also manufactures tests for the immunoassay module of its next-generation Atellica Solution.
Describing the expansion project as “largely completed,” Healthineers previously committed to hiring at least another 400 employees through the expansion project. To date, it’s created more than 275 positions, or about 70% of its target, in the past two years—while saying the project could create up to 700 permanent jobs by 2026.
“The $300 million investment Siemens Healthineers is making in the Walpole facility exemplifies the company’s broader strategy for investing in the U.S.—our largest market—and for furthering our ability to innovate transformative healthcare solutions that can improve the lives of the patients served by our products,” said Deepak Nath, Ph.D., Healthineers’ president of laboratory diagnostics.
“The U.S. is an extremely vital production location for Siemens Healthineers, as well as one of the most important research centers, and a key base from which the company exports globally,” Nath added.
Each year, Healthineers provides more than 10 billion laboratory diagnostic tests globally, making it the fourth-largest medtech company by total 2017 sales, which grossed about $15.5 billion.